GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Bcl2 | decreases expression | EXP | | 6480464 | CTD | Melatonin results in decreased expression of BCL2 mRNA | PMID:16499559 | Bcl2 | multiple interactions | EXP | | 6480464 | CTD | [Puromycin Aminonucleoside co-treated with Melatonin] results in increased expression of BCL2 protein; Melatonin inhibits the reaction [decamethrin results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [Galactose results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [Indomethacin results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [Methionine results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [sodium arsenite results in increased activity of BCL2 protein]; Melatonin inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]; Verteporfin inhibits the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]] | PMID:14993511 PMID:16213988 PMID:17645694 PMID:18715270 PMID:18724894 PMID:19220725 PMID:20041988 PMID:34673010 PMID:35093381 | Bcl2 | affects localization | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | Melatonin affects the localization of BCL2 protein | PMID:18339127 | Bcl2 | decreases expression | ISO | Bcl2 (Mus musculus) | 6480464 | CTD | Melatonin results in decreased expression of BCL2 protein | PMID:14690559 | Bcl2 | decreases expression | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | Melatonin results in decreased expression of BCL2 mRNA; Melatonin results in decreased expression of BCL2 protein | PMID:33507000 | Bcl2 | increases expression | ISO | Bcl2 (Mus musculus) | 6480464 | CTD | Melatonin results in increased expression of BCL2 protein | PMID:12220328 | Bcl2 | increases expression | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | Melatonin results in increased expression of BCL2 protein | PMID:18078454 | Bcl2 | multiple interactions | ISO | Bcl2 (Mus musculus) | 6480464 | CTD | Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [[sodium chromate(VI) results in increased abundance of chromium hexavalent ion] which results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [nickel chloride results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [nickel chloride results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of BCL2 protein]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in decreased expression of BCL2 mRNA]]; TXNRD3 gene mutant form inhibits the reaction [Melatonin inhibits the reaction [nickel chloride results in decreased expression of BCL2 protein]] | PMID:21138475 PMID:23963992 PMID:35643323 PMID:36421005 PMID:38008054 | Bcl2 | multiple interactions | ISO | BCL2 (Homo sapiens) | 6480464 | CTD | [Doxorubicin co-treated with Melatonin] results in decreased expression of BCL2 protein; [Melatonin co-treated with Tretinoin] results in decreased expression of BCL2 protein; [Tretinoin co-treated with Melatonin] results in decreased expression of BCL2 protein; Doxorubicin promotes the reaction [Melatonin results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [[Glucose co-treated with Deferoxamine] results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [Cisplatin affects the expression of BCL2 protein]; Melatonin promotes the reaction [Puromycin results in decreased expression of BCL2 protein] | PMID:10965999 PMID:20333787 PMID:21244482 PMID:24799992 PMID:33507000 PMID:33962019 PMID:9649124 | |
Go Back to source page | Continue to Ontology report |